All Solid Tumors
Cancer Type
Tumor Tissue (FFPE)
Specimen Requirements
8 Working Days
Turnaround Time ¹
ACTDrug®+ is an NGS-based test, which sequences 40 druggable genes, 13 fusion genes, and more than 350 fusion transcripts simultaneously from cancer specimens.
Targeted Cancer Genomic Profiling Service
40
Cancer Genes
13
Fusion Genes
350
Fusion Transcripts
Hallmarks
Drug-Target-Based Panel
Sequences 40 actionable genes,13 fusion genes and more than 350 fusion transcripts with genetic alterations.
Short Turnaround Time
Provides professional solutions within 8 working days (starting from the date of receipt of approved samples at our CAP-accredited laboratory).
High Sensitivity
Uses the NGS platform for microscale specimens.
Tailored Drug Options
Analyzes single nucleotide variation (SNV), small insertion/deletion (InDel), copy number variation (CNV)and fusion gene to provide tailored drug options.
Pioneering Bioinformatics
Integrates cancer biology, medical biology, molecular biology, cell biology, immunology, bioinformatics, data science and pharmaceutical biology to provide insightful interpretation of the data analyses.
Summary
Select Drugs for Your Cancer Patient
Provides tailored drug options through precise genomic profiling for important actionable genes.
A Precise Choice for Cancer Genomic Profiling
ACTDrug®+ is a next-generation sequencing (NGS)-based assay, which sequences 40 actionable genes, 13 fusion genes and more than 350 fusion transcripts simultaneously from cancer specimens in our CAP-accredited laboratory. This assay is specially designed for patients with breast, lung, colorectal or gastric cancers, providing tailored genomic profiling and recommendations of targeted drugs approved by the US FDA.
Explore Various Genetic Alterations for More Precise Therapeutic Implication
ACTDrug®+ performs various genetic variation analyses. In addition to single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides copy number variation (CNV) analysis for 22 genes and fusion gene detection for more precise determination of potential implications.
For All Solid Tumors
Selects the most suitable treatment for newly diagnosed patients based on actionable genetic mutations.
Precise Reporting
Considers targeted therapies and hormonal therapies approved by US FDA or in clinical trials.
Technical Specifications
Next Generation Sequencing (NGS)
40 actionable genes
Specimen Requirements2
Tumor tissue (FFPE)
Sequencing Mean Depth
≥ 800 x
Hotspots
>3800
ACTFusion™
Comprehensive testing of 13 fusion genes and more than 350 fusion transcripts
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
- Please refer to our specimen instructions.
